| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
5alpha-Reductase (5alpha-R)
|
|---|---|
| ln Vitro |
12-O-Methylcarnosic acid (12-Methoxycarnosic acid; 5 μM) suppresses the 66.7% androgen-dependent growth of LNCaP cells[1]. 12-At 78 μg/mL, 12-O-methylcarnosic acid exhibits antibacterial action against S. aureus[2].
In LNCaP human prostate cancer cells, 12-O-Methylcarnosic acid (5 uM) inhibits androgen-dependent proliferation by 66.7%. It also shows antimicrobial activity against S. aureus at 78 ug/mL. Additionally, it activates peroxisome proliferator-activated receptor (PPAR)gamma and suppresses melanin production via tyrosinase downregulation in HMV-II melanoma cells. |
| ln Vivo |
No specific in vivo data for the pure compound alone; however, oral administration of Rosmarinus officinalis leaf extract (enriched in carnosic acid derivatives) promotes hair growth in animal models. Based on related compounds, it may exhibit oral bioavailability and pharmacokinetic parameters suitable for further evaluation in metabolic and dermatological disease models.
|
| Enzyme Assay |
Enzyme inhibition assays using human recombinant 5alpha-reductase. 12-O-Methylcarnosic acid is incubated with the enzyme and the substrate (testosterone or androstenedione) in the presence of NADPH as a cofactor. After incubation at 37degC for a defined time, the reaction is stopped by organic solvent extraction. The product (dihydrotestosterone or androstenedione) is quantified by HPLC or LC-MS/MS. The IC50 value is calculated by fitting a dose-response curve (IC50 = 61.7 uM).
|
| Cell Assay |
LNCaP human prostate cancer cells are cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum and antibiotics. Cells are seeded in 96-well plates and treated with varying concentrations of 12-O-Methylcarnosic acid (1-100 uM) for 48-72 hours. Cell proliferation is assessed using the MTT or CCK-8 assay. The percentage of inhibition is calculated relative to vehicle-treated controls (DMSO). The IC50 for antiproliferation is determined by non-linear regression analysis.
|
| Animal Protocol |
No published in vivo animal study specific to this compound alone; however, related phenolic diterpenes from Rosmarinus officinalis are typically dosed orally (gavage) or intraperitoneally at 10-50 mg/kg in rodents. Pharmacodynamic endpoints include serum lipid profiles, antioxidant status, and histopathology of target organs (liver, prostate).
|
| ADME/Pharmacokinetics |
No specific pharmacokinetic data for this compound; based on chemical similarity to carnosic acid, it is expected to be absorbed after oral administration, metabolized by phase I and II enzymes in the liver, and excreted via bile and urine. Plasma half-life in rodents likely ranges from 1-4 hours.
|
| Toxicity/Toxicokinetics |
No specific toxicity data for 12-O-Methylcarnosic acid; related diterpenes from rosemary show low acute toxicity with oral LD50 > 2000 mg/kg in rodents. Chronic administration (up to 90 days) at therapeutic doses (10-50 mg/kg) is generally well tolerated without significant organ toxicity. However, high doses may cause mild gastrointestinal disturbances or hepatotoxicity due to reactive metabolite formation.
|
| References | |
| Additional Infomation |
According to reports, 12-O-methylsarsamarinic acid is found in sage, oregano, and other organisms for which data is available.
This compound is a research tool for studying 5alpha-reductase inhibition and androgen-dependent prostate cancer. It exhibits diverse biological activities beyond 5alpha-R inhibition, including PPARgamma activation, antioxidant effects, and antimicrobial properties. The IC50 for 5alpha-reductase is 61.7 uM. It is a natural product-derived agent with potential applications in benign prostatic hyperplasia, acne, alopecia, and metabolic disorders. Not approved for clinical use. |
| Molecular Formula |
C21H30O4
|
|---|---|
| Molecular Weight |
346.46
|
| Exact Mass |
346.214
|
| CAS # |
62201-71-2
|
| PubChem CID |
9974918
|
| Appearance |
White to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
505.1±50.0 °C at 760 mmHg
|
| Flash Point |
173.3±23.6 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
5.23
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
25
|
| Complexity |
514
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC(C)C1=C(C(=C2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C(=O)O)O)OC
|
| InChi Key |
QQNSARJGBPMQDI-YCRPNKLZSA-N
|
| InChi Code |
InChI=1S/C21H30O4/c1-12(2)14-11-13-7-8-15-20(3,4)9-6-10-21(15,19(23)24)16(13)17(22)18(14)25-5/h11-12,15,22H,6-10H2,1-5H3,(H,23,24)/t15-,21+/m0/s1
|
| Chemical Name |
(4aR,10aS)-5-hydroxy-6-methoxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (144.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8863 mL | 14.4317 mL | 28.8634 mL | |
| 5 mM | 0.5773 mL | 2.8863 mL | 5.7727 mL | |
| 10 mM | 0.2886 mL | 1.4432 mL | 2.8863 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
